Therapeutic method for mesothelioma
AssigneesNational University Corporation Kanazawa University, Kyowa Hakko Kirin Co., Ltd.
InventorsSeiji Yano, Yusuke Machino, Yui Suzuki
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved by diagnosing and treating GM2 positive mesothelioma patients with a diagnostic agent and a therapeutic agent that comprise an anti-ganglioside GM2 antibody as an active ingredient.
Claims22
A method for treating mesothelioma, comprising administering as an active ingredient an antibody or a fragment thereof that binds to a ganglioside GM2 into a subject in need thereof,
- wherein the antibody comprises heavy chain (H-chain) complementarity determining regions (CDRs) 1 to 3 having the amino acid sequences of SEQ ID NOS:
- 1 to 3, respectively, and light chain (L-chain) CDRs 1 to 3 having the amino acid sequences of SEQ ID NOS:
- 4 to 6, respectively.
A method for treating mesothelioma, comprising administering as an active ingredient an antibody or a fragment thereof that binds to a ganglioside GM2 into a subject in need thereof,
- wherein the antibody is one selected from the group consisting of:
- an antibody that comprises an H-chain variable region (VH) having the amino acid sequence of SEQ ID NO:
- 7 and an L-chain variable region (VL) having the amino acid sequence of SEQ ID NO:
- 8;
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 7 and a VL having the amino acid sequence of SEQ ID NO:
- 9;
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 10 and a VL having the amino acid sequence of SEQ ID NO:
- 8;
- and
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 10 and a VL having the amino acid sequence of SEQ ID NO:
- 11.
A pharmaceutical composition comprising:
- an antibody or a fragment thereof that binds to a ganglioside GM2;
- and
- a pharmaceutically acceptable carrier,
- wherein said antibody comprises heavy chain complementarity determining regions (CDRs) 1 to 3 having the amino acid sequences of SEQ ID NOS:
- 1 to 3, respectively, and light chain CDRs 1 to 3 having the amino acid sequences of SEQ ID NOS:
- 4 to 6, respectively.
A pharmaceutical composition comprising:
- an antibody or a fragment thereof that binds to a ganglioside GM2;
- and
- a pharmaceutically acceptable carrier,
- said antibody is one selected from the group consisting of:
- an antibody that comprises an H-chain variable region (VH) having the amino acid sequence of SEQ ID NO:
- 7 and an L-chain variable region (VL) having the amino acid sequence of SEQ ID NO:
- 8;
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 7 and a VL having the amino acid sequence of SEQ ID NO:
- 9;
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 10 and a VL having the amino acid sequence of SEQ ID NO:
- 8;
- and
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 10 and a VL having the amino acid sequence of SEQ ID NO:
- 11.
A method for diagnosing mesothelioma, comprising detecting or assaying a GM2, cell, or tissue in a sample by employing an antibody or a fragment thereof that binds to a ganglioside GM2,
- wherein the antibody comprises heavy chain (H-chain) complementarity determining regions (CDRs) 1 to 3 having the amino acid sequences of SEQ ID NOS:
- 1 to 3, respectively, and light chain (L-chain) CDRs 1 to 3 having the amino acid sequences of SEQ ID NOS:
- 4 to 6, respectively;
- and
- wherein the antibody is a recombinant antibody selected from the group consisting of a human chimeric antibody, humanized antibody, and human antibody.
A method for diagnosing mesothelioma, comprising detecting or assaying a GM2, cell, or tissue in a sample by employing an antibody or a fragment thereof that binds to a ganglioside GM2, wherein the antibody is one selected from the group consisting of:
- an antibody that comprises an H-chain variable region (VH) having the amino acid sequence of SEQ ID NO:
- 7 and an L-chain variable region (VL) having the amino acid sequence of SEQ ID NO:
- 8;
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 7 and a VL having the amino acid sequence of SEQ ID NO:
- 9;
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 10 and a VL having the amino acid sequence of SEQ ID NO:
- 8;
- and
- an antibody that comprises a VH having the amino acid sequence of SEQ ID NO:
- 10 and a VL having the amino acid sequence of SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.